Form 4 for CPHI CHINA PHARMA HOLDINGS, INC.
Accepted 2021-09-13 00:00:00 ET · period of report 2021-09-09 · accession 0001213900-21-047830 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021-09-13 | 2021-09-09 | CPHI | Li Zhilin | CEO, Interim CFO, Dir, 10% | A - Grant | $0.67 | +1.76M | 13.81M | +15% | +$1.18M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-09-09 | A | A | 1,760,000 | $0.67 | 13,810,000 | D | — | — | (F1) On September 9, 2021, the reporting person was granted 1,760,000 shares of Issuer's common stock under the Issuer's 2010 Long-Term Incentive Plan, vesting immediately with no restrictions, as partial offset of her accrued but unpaid cash compensation by serving as the Issuer's Chairman of the Board, Chief Executive Officer and interim Chief Financial Officer. |